Bilateral Hip Replacement Surgery in India and UAE | Complete Patient Guide

Eligible Candidates (Indications):

• Bilateral severe hip osteoarthritis (Kellgren-Lawrence Grade III–IV on weight-bearing X-rays of both hips)

• Bilateral avascular necrosis (AVN) of the femoral head, Ficat-Arlet Stage III–IV bilaterally

• Bilateral hip involvement in rheumatoid arthritis or ankylosing spondylitis refractory to disease-modifying therapy (DMARDs/biologics)

• Bilateral post-traumatic arthritis following acetabular or femoral neck fractures

• Patients with a Harris Hip Score (HHS) below 60 in both hips, or WOMAC pain subscale scores indicating severe bilateral functional limitation

• Patients who have failed at least 6 months of conservative management including physiotherapy, activity modification, and pharmacologic analgesia

• Medically fit for a prolonged anesthetic (ASA Class I or II; carefully selected ASA Class III after optimization)

Required Pre-Operative Diagnostics:

• Standing AP pelvis and lateral X-rays of both hips (Kellgren-Lawrence grading)

• MRI of both hips (if AVN or soft-tissue pathology suspected)

• DEXA scan (bone mineral density — determines cemented vs. cementless stem choice)

• 12-lead ECG and transthoracic echocardiography (ECHO) — to assess cardiac reserve for bilateral procedure

• Complete blood count, coagulation profile (PT/INR/aPTT), metabolic panel, HbA1c

• Pulmonary function tests (PFTs) if history of COPD or restrictive lung disease

• Pre-operative autologous blood donation or crossmatch and type & screen (2–4 units PRBC)

• Caprini DVT Risk Score and lower-limb Doppler ultrasound if high-risk

• Anesthesia fitness assessment including airway evaluation and cardiac stress test if indicated

Contraindications:

• Active systemic or local infection (absolute contraindication — risk of prosthetic joint infection)

• ASA Class IV or V — severe cardiopulmonary compromise precluding safe prolonged anesthesia

• Uncontrolled coagulopathy or active anticoagulation not bridgeable

• Morbid obesity (BMI > 40) — relative contraindication; staged approach preferred

• Active malignancy with short life expectancy

• Severe peripheral vascular disease compromising wound healing

• Profound osteoporosis without prior optimization (relative; may require cemented fixation strategy)

• Patient unable or unwilling to comply with post-operative rehabilitation and weight-bearing protocols

Standard Bilateral Total Hip Replacement (Open Approach):

The posterior (Moore/Southern) approach remains the most widely used globally, offering excellent acetabular visualization. The anterolateral (Watson-Jones) or direct lateral (Hardinge) approach is preferred by some surgeons for reduced posterior capsule disruption. In bilateral cases, both hips are addressed in sequence under the same anesthetic, typically completing each side in 60–90 minutes. General or spinal-epidural combined anesthesia is used, with spinal anesthesia increasingly preferred for its lower systemic side-effect profile and superior VTE risk reduction.

Minimally Invasive Surgery (MIS) Bilateral THR:

Single-incision MIS techniques (anterior or anterolateral muscle-sparing approaches) use incisions of 7–10 cm versus the traditional 15–20 cm, reducing soft tissue trauma, blood loss, and early post-operative pain. The Direct Anterior Approach (DAA) — performed on a specialized orthopedic traction table (e.g., ProFx™ or Hana table) — exploits the internervous and intermuscular plane between the tensor fasciae latae and sartorius, preserving all short external rotators and the posterior capsule, thereby significantly lowering the dislocation risk. For bilateral DAA-THR, the patient remains supine throughout, enabling a single surgical drape and position setup for both hips.

Robotic-Assisted Bilateral THR (Mako™ SmartRobotics™ / VELYS™):

Robotic arm-assisted arthroplasty — available at premium partner centers in India (Mumbai, Delhi, Chennai) and the UAE (Dubai, Abu Dhabi) — uses pre-operative CT-based 3D planning to define patient-specific implant sizing, positioning targets (cup abduction angle 40° ± 5°, anteversion 15° ± 5°), and leg-length equalization. The robotic arm provides haptic boundary enforcement, preventing the surgeon from reaming or positioning implants outside pre-planned parameters. Evidence shows robotic-assisted THR achieves superior component positioning accuracy (>95% within the Lewinnek safe zone), reduced leg-length discrepancy (<3 mm), and lower early revision rates compared to conventional freehand technique — advantages that are magnified in the bilateral setting where symmetry is paramount.

Bearing Surface Selection:

• Ceramic-on-Highly Cross-Linked Polyethylene (CoC-HXLPE): Most commonly recommended; excellent wear profile, low fracture risk, suitable for all activity levels.

• Ceramic-on-Ceramic (CoC): Lowest wear rate; preferred in younger, active patients (<55 years); risk of audible squeaking (~1–2%).

• Cobalt-Chromium-on-HXLPE: Cost-effective option with excellent 15-year survivorship data.

• Oxidized Zirconium (Oxinium™) on HXLPE: Intermediate cost; scratch-resistant; useful in patients with metal sensitivity.

Stem Fixation:

• Cementless (press-fit) porous-coated stems: Preferred for patients with good bone quality (T-score > -1.0 on DEXA); allows biological osseointegration.

• Cemented stems: Indicated for osteoporotic bone (T-score < -2.5), elderly patients, or those with abnormal canal geometry.

• Hybrid fixation: Cementless cup + cemented stem — a common compromise in patients with moderate bone density.

Staged vs. Simultaneous Approach:

Simultaneous bilateral THR (SBTHA) is preferred for patients with symmetric bilateral disease, good cardiopulmonary reserve, and strong patient preference to minimize total recovery time. Staged bilateral THR (3–6 months apart) is chosen for patients with significant cardiac or pulmonary comorbidities, morbid obesity, or asymmetric disease severity. GAF Healthcare's partner orthopedic surgeons conduct a thorough multidisciplinary team (MDT) review — including orthopedics, anesthesiology, cardiology, and hematology — to individualize this decision for each international patient.

Blood Management Protocol:

Intraoperative and post-operative tranexamic acid (TXA) — administered intravenously (1g IV at incision) and topically (2g intra-articular) — reduces mean blood loss by 30–50% in bilateral cases, minimizing allogenic transfusion requirements. Cell salvage (intraoperative autotransfusion) is deployed in complex revision cases or anticipated high-volume blood loss.

Phase 1 — Remote Pre-Operative Assessment (2–4 weeks before travel):

• Patient submits imaging (X-rays, MRI, DEXA) and medical records to GAF Healthcare's clinical coordination team.

• Assigned specialist orthopedic surgeon reviews files and issues a digital surgical recommendation report including implant selection, approach, and estimated blood loss risk.

• GAF Healthcare facilitates pre-operative teleconsultation with the operating surgeon and anesthesiologist.

• E-Medical Visa (India) or UAE entry visa application initiated by GAF Healthcare's visa support team.

• Pre-operative optimization instructions issued: HbA1c target <7.5%, blood pressure <140/90 mmHg, cessation of NSAIDs and antiplatelet agents (aspirin 7–10 days; clopidogrel 5–7 days prior to surgery), and iron supplementation if hemoglobin <12 g/dL.

Phase 2 — Arrival and In-Hospital Pre-Operative Workup (Days 1–2):

• Airport pickup by GAF Healthcare's dedicated ground team.

• Admission to partner hospital; in-person anesthesia assessment.

• Repeat CBC, coagulation profile, ECG, and ECHO if not done within 30 days.

• Blood crossmatch; TXA protocol initiated.

• Surgical site skin preparation; DVT prophylaxis commenced (LMWH — e.g., enoxaparin — started 12 hours pre-operatively or mechanically with pneumatic compression devices).

• Patient and family/attendant orientation by GAF Healthcare's hospital liaison and interpreter.

Phase 3 — Surgery Day (Day 2 or 3):

• Combined spinal-epidural or general anesthesia administered.

• Simultaneous bilateral THR performed: First hip completed (~60–90 minutes), then second hip (~60–90 minutes); total operative time 2.5–4 hours.

• Robotic arm guidance (if selected) used for both acetabular cup and femoral stem positioning.

• TXA administered intravenously at incision and topically before closure on each side.

• Intra-operative cell salvage active throughout.

• Wound closure with absorbable sutures or staples; waterproof dressings applied.

• Transfer to recovery room; vital signs monitored; spinal block regression confirmed.

Phase 4 — Acute In-Hospital Recovery (Days 3–10):

• Day 1 post-op: Patient mobilized to sitting position with physiotherapist; foot/ankle pump exercises commenced immediately.

• Day 2 post-op: Standing and weight-bearing as tolerated (WBAT) with walking frame initiated — a hallmark of ERAS-protocol bilateral THR.

• Pain managed via multimodal analgesia: scheduled acetaminophen + celecoxib (COX-2 inhibitor) + pregabalin; opioids reserved for breakthrough pain only.

• DVT prophylaxis continued with LMWH and/or rivaroxaban (10 mg OD) for 5 weeks post-discharge.

• Daily physiotherapy sessions: hip strengthening, gait retraining, stair practice.

• Hemoglobin monitored; IV iron (e.g., ferric carboxymaltose) administered if Hb <9 g/dL without transfusion trigger.

• Wound check at Day 7; staple/clip removal if non-absorbable used.

• Discharge planning initiated: home exercise program provided, assistive devices (bilateral elbow crutches or rollator) fitted.

• Discharge from hospital: Day 7–10 post-op.

Phase 5 — Post-Discharge In-Country Rehabilitation (Weeks 2–6):

• Patient transferred to GAF Healthcare's partner serviced apartment or recovery facility near the hospital.

• Outpatient physiotherapy 5 days/week: progressive hip abductor and extensor strengthening, proprioception training, hydrotherapy (from Week 3 if wounds healed).

• Wound review at 2 weeks; suture removal if needed.

• X-ray review at 4–6 weeks to confirm implant position and osseointegration.

• Hip precautions maintained (for posterior approach: no flexion >90°, no internal rotation, no adduction crossing midline); relaxed for anterior approach patients.

• DVT prophylaxis completed at 5 weeks.

Phase 6 — Fit-to-Fly Assessment & Departure (Week 6–8):

• Final orthopedic consultation with post-operative X-rays and functional assessment.

• Formal fit-to-fly clearance letter issued.

• Airline assistance arranged: wheelchair assistance, bulkhead seating, and compression stockings for flight.

• GAF Healthcare coordinates handover notes and implant cards to home country orthopedic team.

• Continued physiotherapy and full recovery expected at 3–6 months post-surgery; return to low-impact activities (swimming, cycling) at 3 months; high-impact activities (hiking, doubles tennis) at 6 months.